HanchorBio Inc.

HanchorBio Inc. is a clinical-stage global pharmaceutical company established in October 2020 in Taipei, Taiwan, dedicated to the research and development of novel biologics in immuno-oncology. The company's mission is to advance immuno-oncology therapies through the development of cutting-edge designer biologics utilizing novel modalities. HanchorBio leverages its proprietary FBDB™ (Fc-Based Designer Biologics) platform, advanced protein engineering, and AI-assisted drug design to address challenges in cancer immunotherapy.

The company's core technology, the FBDB™ platform, focuses on developing next-generation immuno-oncology fusion protein therapeutics by using the antibody Fc region as a backbone for engineered anti-cancer molecules. HanchorBio's pipeline includes its flagship product HCB101, a best-in-class immuno-oncology biologic targeting CD47, which is progressing into clinical trials across China, the United States, and Taiwan. Additionally, the pipeline features next-generation tri-functional immuno-oncology biologics such as HCB301 and HCB303, with eight biologics based on the FBDB platform currently in development.

Founded by Dr. Liu Scott, HanchorBio Inc. was listed on Taiwan's Emerging Stock Board (TPEx: 7827) in June 2025. Recent developments include a collaboration with National Yang Ming Chiao Tung University for AI-enabled drug discovery in April 2026 and a partnership with Bloomberg to enhance strategic intelligence across drug development and global market execution. The company also recently completed the first 2,000L GMP clinical batch production of HCB101 and signed a licensing deal for HCB101 with Fosun's Henlius in July 2025. HanchorBio maintains R&D and multi-center clinical sites across Taiwan, the U.S., and China.